His-CYGB deactivates HSCs and inhibits liver fibrosis (IMAGE)

Osaka City University

His-CYGB deactivates HSCs and inhibits liver fibrosis

Caption

6His tagged recombinant human CYGB (His-CYGB) was endocytosed into the HSCs via Clathrin-mediated pathway, scavenged ROS, such as O2- and OH-, and induced IFN-β secretion mediated by TANK binding kinase 1 (TBK1), resulting in HSC deactivation and inhibition of αSMA and collagen gene expressions in vitro and in vivo. In total, His-CYGB could be utilized as anti-fibrotic therapy in human liver cirrhosis.

Credit

Kawada/Osaka City University

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.